Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report.

Barchiesi G, Krasniqi E, Barba M, Giulia MD, Pizzuti L, Massimiani G, Ciliberto G, Vici P.

Medicine (Baltimore). 2019 Sep;98(37):e17135. doi: 10.1097/MD.0000000000017135.

2.

Equine viral encephalitis: prevalence, impact, and management strategies.

Barba M, Fairbanks EL, Daly JM.

Vet Med (Auckl). 2019 Aug 7;10:99-110. doi: 10.2147/VMRR.S168227. eCollection 2019.

3.

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting.

Di Benedetto A, Ercolani C, Pizzuti L, Angelucci D, Sergi D, Marinelli C, Iezzi L, Sperati F, Terrenato I, Mazzotta M, Mariani L, Vizza E, Paoletti G, Tomao S, Maugeri-Saccà M, Barba M, Tinari N, Natoli C, Ciliberto G, Grassadonia A, Vici P.

Ther Adv Med Oncol. 2019 Aug 18;11:1758835919853192. doi: 10.1177/1758835919853192. eCollection 2019.

4.

Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer.

Maselli A, Parlato S, Puglisi R, Raggi C, Spada M, Macchia D, Pontecorvi G, Iessi E, Pagano MT, Cirulli F, Gabriele L, Carè A, Vici P, Pizzuti L, Barba M, Matarrese P, Pierdominici M, Ortona E.

Cells. 2019 Jul 19;8(7). pii: E750. doi: 10.3390/cells8070750.

5.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583. [Epub ahead of print]

PMID:
31330065
6.

Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.

Goeman F, De Nicola F, Scalera S, Sperati F, Gallo E, Ciuffreda L, Pallocca M, Pizzuti L, Krasniqi E, Barchiesi G, Vici P, Barba M, Buglioni S, Casini B, Visca P, Pescarmona E, Mazzotta M, De Maria R, Fanciulli M, Ciliberto G, Maugeri-Saccà M.

J Thorac Oncol. 2019 Jul 16. pii: S1556-0864(19)30560-X. doi: 10.1016/j.jtho.2019.07.003. [Epub ahead of print]

PMID:
31323387
7.

DNA metabarcoding-Need for robust experimental designs to draw sound ecological conclusions.

Zinger L, Bonin A, Alsos IG, Bálint M, Bik H, Boyer F, Chariton AA, Creer S, Coissac E, Deagle BE, De Barba M, Dickie IA, Dumbrell AJ, Ficetola GF, Fierer N, Fumagalli L, Gilbert MTP, Jarman S, Jumpponen A, Kauserud H, Orlando L, Pansu J, Pawlowski J, Tedersoo L, Thomsen PF, Willerslev E, Taberlet P.

Mol Ecol. 2019 Apr;28(8):1857-1862. doi: 10.1111/mec.15060. Epub 2019 Apr 29. No abstract available.

8.

The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer.

Valentini V, Gambacorta MA, Cellini F, Aristei C, Coco C, Barbaro B, Alfieri S, D'Ugo D, Persiani R, Deodato F, Crucitti A, Lupattelli M, Mantello G, Navarria F, Belluco C, Buonadonna A, Boso C, Lonardi S, Caravatta L, Barba MC, Vecchio FM, Maranzano E, Genovesi D, Doglietto GB, Morganti AG, La Torre G, Pucciarelli S, De Paoli A.

Radiother Oncol. 2019 May;134:110-118. doi: 10.1016/j.radonc.2018.11.023. Epub 2019 Feb 7.

PMID:
31005204
9.

Quantitative analysis of free water in ionic liquid-water mixtures.

Barba MI, Larrechi MS, Coronas A.

Talanta. 2019 Jul 1;199:407-414. doi: 10.1016/j.talanta.2019.02.087. Epub 2019 Feb 27.

PMID:
30952277
10.

Public engagement in science: Mapping out and understanding the practice of science communication in Latin America.

Barba MLP, Castillo JPGD, Massarani L.

An Acad Bras Cienc. 2019 Mar 21;91(1):e20171000. doi: 10.1590/0001-3765201920171000.

11.

An Evidence-Based Approach to Precepting New Nurses.

Barba M, Valdez-Delgado K, VanFosson CA, Caldwell NW, Boyer S, Robbins J, Mann-Salinas EA.

Am J Nurs. 2019 Mar;119(3):62-67. doi: 10.1097/01.NAJ.0000554036.68497.61.

PMID:
30801318
12.

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer.

Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, Vici P.

J Clin Med. 2019 Feb 18;8(2). pii: E254. doi: 10.3390/jcm8020254. Review.

13.

Corrigendum to "BBS9 gene in nonsyndromic craniosynostosis: Role of the primary cilium in the aberrant ossification of the suture osteogenic niche" [Bone 112 (July 2018) 58-70].

Barba M, Di Pietro L, Massimi L, Geloso MC, Frassanito P, Caldarelli M, Michetti F, Della Longa S, Romitti PA, Di Rocco C, Arcovito A, Parolini O, Tamburrini G, Bernardini C, Boyadjiev SA, Lattanzi W.

Bone. 2019 Apr;121:293. doi: 10.1016/j.bone.2019.02.004. Epub 2019 Feb 15. No abstract available.

14.

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.

Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, Quinzii A, Camplese A, Di Marino P, Peri M, Veschi S, Alberti S, Gamucci T, Di Gioacchino M, De Tursi M, Natoli C, Tinari N.

Breast. 2019 Apr;44:33-38. doi: 10.1016/j.breast.2018.12.014. Epub 2019 Jan 2.

15.

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.

Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, Pizzuti L, Maugeri-Saccà M, Marchetti P, Cognetti G, De Tursi M, Natoli C, Barba M, Tinari N.

J Clin Med. 2018 Dec 12;7(12). pii: E542. doi: 10.3390/jcm7120542.

16.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airoldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P.

J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.

PMID:
30536609
17.

Cardiometabolic and Muscular Fatigue Responses to Different CrossFit® Workouts.

Maté-Muñoz JL, Lougedo JH, Barba M, Cañuelo-Márquez AM, Guodemar-Pérez J, García-Fernández P, Lozano-Estevan MDC, Alonso-Melero R, Sánchez-Calabuig MA, Ruíz-López M, de Jesús F, Garnacho-Castaño MV.

J Sports Sci Med. 2018 Nov 20;17(4):668-679. eCollection 2018 Dec.

18.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P.

Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7.

19.

Body size determines soil community assembly in a tropical forest.

Zinger L, Taberlet P, Schimann H, Bonin A, Boyer F, De Barba M, Gaucher P, Gielly L, Giguet-Covex C, Iribar A, Réjou-Méchain M, Rayé G, Rioux D, Schilling V, Tymen B, Viers J, Zouiten C, Thuiller W, Coissac E, Chave J.

Mol Ecol. 2019 Feb;28(3):528-543. doi: 10.1111/mec.14919. Epub 2018 Nov 22.

PMID:
30375061
20.

Graphene Oxide Induced Osteogenesis Quantification by In-Situ 2D-Fluorescence Spectroscopy.

Palmieri V, Barba M, Di Pietro L, Conti C, De Spirito M, Lattanzi W, Papi M.

Int J Mol Sci. 2018 Oct 26;19(11). pii: E3336. doi: 10.3390/ijms19113336.

21.

Differential toxicity of processed and non-processed states of CoCrMo degradation products generated from a hip simulator on neural cells.

Rani Bijukumar D, Segu A, Mou Y, Ghodsi R, Shokufhar T, Barba M, Li XJ, Thoppil Mathew M.

Nanotoxicology. 2018 Nov;12(9):941-956. doi: 10.1080/17435390.2018.1498929. Epub 2018 Sep 25.

PMID:
30251573
22.

The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression.

Buglioni S, Melucci E, Sperati F, Pallocca M, Terrenato I, De Nicola F, Goeman F, Casini B, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vici P, Sergi D, Pizzuti L, Di Lauro L, Mazzotta M, Barba M, Fanciulli M, Vitale I, De Maria R, Ciliberto G, Maugeri-Saccà M.

Oncoimmunology. 2018 Apr 24;7(8):e1457602. doi: 10.1080/2162402X.2018.1457602. eCollection 2018.

23.

Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.

López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M, Dávila D, Salvador-Tormo N, Guzmán M, Sepúlveda JM, Sánchez-Gómez P, Lorente M, Velasco G.

Biochem Pharmacol. 2018 Nov;157:266-274. doi: 10.1016/j.bcp.2018.09.007. Epub 2018 Sep 7.

24.

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.

Pallocca M, Goeman F, De Nicola F, Melucci E, Sperati F, Terrenato I, Pizzuti L, Casini B, Gallo E, Amoreo CA, Vici P, Di Lauro L, Buglioni S, Diodoro MG, Pescarmona E, Mazzotta M, Barba M, Fanciulli M, De Maria R, Ciliberto G, Maugeri-Saccà M.

J Transl Med. 2018 Sep 4;16(1):247. doi: 10.1186/s12967-018-1607-3.

25.

Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer.

De Nicola F, Goeman F, Pallocca M, Sperati F, Pizzuti L, Melucci E, Casini B, Amoreo CA, Gallo E, Diodoro MG, Buglioni S, Mazzotta M, Vici P, Sergi D, Di Lauro L, Barba M, Pescarmona E, Ciliberto G, De Maria R, Fanciulli M, Maugeri-Saccà M.

Oncogenesis. 2018 Jul 22;7(7):55. doi: 10.1038/s41389-018-0066-2.

26.

Anticoagulation for perioperative thromboprophylaxis in people with cancer.

Matar CF, Kahale LA, Hakoum MB, Tsolakian IG, Etxeandia-Ikobaltzeta I, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA.

Cochrane Database Syst Rev. 2018 Jul 11;7:CD009447. doi: 10.1002/14651858.CD009447.pub3. Review.

27.

Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.

Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, Barba M, Yosuico VE, Schünemann H, Akl EA.

Cochrane Database Syst Rev. 2018 Jun 19;6:CD006650. doi: 10.1002/14651858.CD006650.pub5. Review.

28.

Anticoagulation for people with cancer and central venous catheters.

Kahale LA, Tsolakian IG, Hakoum MB, Matar CF, Barba M, Yosuico VE, Terrenato I, Sperati F, Schünemann H, Akl EA.

Cochrane Database Syst Rev. 2018 Jun 1;6:CD006468. doi: 10.1002/14651858.CD006468.pub6. Review.

29.

Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.

Mandoj C, Pizzuti L, Sergi D, Sperduti I, Mazzotta M, Di Lauro L, Amodio A, Carpano S, Di Benedetto A, Botti C, Ferranti F, Antenucci A, D'Alessandro MG, Marchetti P, Tomao S, Sanguineti G, Giordano A, Maugeri-Saccà M, Ciliberto G, Conti L, Vici P, Barba M.

J Transl Med. 2018 May 16;16(1):129. doi: 10.1186/s12967-018-1511-x.

30.

BBS9 gene in nonsyndromic craniosynostosis: Role of the primary cilium in the aberrant ossification of the suture osteogenic niche.

Barba M, Di Pietro L, Massimi L, Geloso MC, Frassanito P, Caldarelli M, Michetti F, Della Longa S, Romitti PA, Di Rocco C, Arcovito A, Parolini O, Tamburrini G, Bernardini C, Boyadjiev SA, Lattanzi W.

Bone. 2018 Jul;112:58-70. doi: 10.1016/j.bone.2018.04.013. Epub 2018 Apr 17. Erratum in: Bone. 2019 Apr;121:293.

31.

Dual-Polarization Ku-Band Compact Spaceborne Antenna Based on Dual-Reflectarray Optics.

Tienda C, Encinar JA, Barba M, Arrebola M.

Sensors (Basel). 2018 Apr 5;18(4). pii: E1100. doi: 10.3390/s18041100.

32.

Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study.

Barnabei A, Strigari L, Persichetti A, Baldelli R, Rizza L, Annoscia C, Lauretta R, Cigliana G, Barba M, De Leo A, Appetecchia M, Torino F.

Front Endocrinol (Lausanne). 2018 Feb 15;9:37. doi: 10.3389/fendo.2018.00037. eCollection 2018.

33.

Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.

Melucci E, Casini B, Ronchetti L, Pizzuti L, Sperati F, Pallocca M, De Nicola F, Goeman F, Gallo E, Amoreo CA, Sergi D, Terrenato I, Vici P, Di Lauro L, Diodoro MG, Pescarmona E, Barba M, Mazzotta M, Mottolese M, Fanciulli M, Ciliberto G, De Maria R, Buglioni S, Maugeri-Saccà M.

J Transl Med. 2018 Feb 5;16(1):22. doi: 10.1186/s12967-018-1385-y.

34.

Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I, Sperati F, Barba M, Schünemann H, Akl EA.

Cochrane Database Syst Rev. 2018 Jan 24;1:CD006649. doi: 10.1002/14651858.CD006649.pub7. Review.

35.

Systemic and local toxicity of metal debris released from hip prostheses: A review of experimental approaches.

Bijukumar DR, Segu A, Souza JCM, Li X, Barba M, Mercuri LG, J Jacobs J, Mathew MT.

Nanomedicine. 2018 Apr;14(3):951-963. doi: 10.1016/j.nano.2018.01.001. Epub 2018 Jan 12. Review.

36.

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.

Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P.

Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16.

37.

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Barba M, Yosuico VED, Terrenato I, Sperati F, Schünemann H, Akl EA.

Cochrane Database Syst Rev. 2017 Dec 29;12:CD006466. doi: 10.1002/14651858.CD006466.pub6. Review.

38.

Ensembl Genomes 2018: an integrated omics infrastructure for non-vertebrate species.

Kersey PJ, Allen JE, Allot A, Barba M, Boddu S, Bolt BJ, Carvalho-Silva D, Christensen M, Davis P, Grabmueller C, Kumar N, Liu Z, Maurel T, Moore B, McDowall MD, Maheswari U, Naamati G, Newman V, Ong CK, Paulini M, Pedro H, Perry E, Russell M, Sparrow H, Tapanari E, Taylor K, Vullo A, Williams G, Zadissia A, Olson A, Stein J, Wei S, Tello-Ruiz M, Ware D, Luciani A, Potter S, Finn RD, Urban M, Hammond-Kosack KE, Bolser DM, De Silva N, Howe KL, Langridge N, Maslen G, Staines DM, Yates A.

Nucleic Acids Res. 2018 Jan 4;46(D1):D802-D808. doi: 10.1093/nar/gkx1011.

39.

Quantitative and automated MALDI-TOF MS-based detection of the plasmid-mediated quinolone resistance determinant AAC(6')-Ib-cr in Enterobacteriaceae.

Oviaño M, Gómara M, Barba MJ, Sparbier K, Pascual Á, Bou G.

J Antimicrob Chemother. 2017 Oct 1;72(10):2952-2954. doi: 10.1093/jac/dkx218. No abstract available.

PMID:
29091187
40.

Preliminary investigation of orally administered benazepril in horses with left-sided valvular regurgitation.

Afonso T, Giguère S, Brown SA, Barton MH, Rapoport G, Barba M, Dembek KA, Toribio RE, Coleman AE.

Equine Vet J. 2018 Jul;50(4):446-451. doi: 10.1111/evj.12773. Epub 2017 Nov 28.

PMID:
29044678
41.

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.

Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Saccà M, Moscetti L, Barba M, Vici P.

Oncotarget. 2017 Apr 9;8(40):69025-69037. doi: 10.18632/oncotarget.16982. eCollection 2017 Sep 15.

42.

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.

Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T.

Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

43.

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.

Moscetti L, Fabbri MA, Natoli C, Vici P, Gamucci T, Sperduti I, Iezzi L, Iattoni E, Pizzuti L, Roma C, Vaccaro A, D'Auria G, Mauri M, Mentuccia L, Grassadonia A, Barba M, Ruggeri EM.

Oncotarget. 2017 Apr 20;8(33):54528-54536. doi: 10.18632/oncotarget.17262. eCollection 2017 Aug 15.

44.

Parenteral anticoagulation in ambulatory patients with cancer.

Akl EA, Kahale LA, Hakoum MB, Matar CF, Sperati F, Barba M, Yosuico VED, Terrenato I, Synnot A, Schünemann H.

Cochrane Database Syst Rev. 2017 Sep 11;9:CD006652. doi: 10.1002/14651858.CD006652.pub5. Review.

45.

Comparison of metal ion levels in patients with hip resurfacing versus total hip arthroplasty.

Forsthoefel CW, Brown NM, Barba ML.

J Orthop. 2017 Aug 31;14(4):561-564. doi: 10.1016/j.jor.2017.07.019. eCollection 2017 Dec.

46.

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.

Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P.

Sci Rep. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.

47.

A method based on near-infrared spectroscopy for the in-situ determination of the ammonia concentration in ammonia/water mixtures in an absorber test bench.

Barba MI, Berdasco M, Salavera D, Larrechi MS, Coronas A.

Talanta. 2017 Dec 1;175:528-534. doi: 10.1016/j.talanta.2017.07.083. Epub 2017 Jul 28.

PMID:
28842028
48.

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.

Di Benedetto A, Ercolani C, Mottolese M, Sperati F, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Humphries MP, Di Lauro L, Barba M, Vitale I, Ciliberto G, Speirs V, De Maria R, Maugeri-Saccà M.

Sci Rep. 2017 Aug 14;7(1):8078. doi: 10.1038/s41598-017-07366-7.

49.

Implementation and outcomes of an evidence-based precepting program for burn nurses.

Robbins JR, Valdez-Delgado KK, Caldwell NW, Yoder LH, Hayes EJ, Barba MG, Greeley HL, Mitchell C, Mann-Salinas EA.

Burns. 2017 Nov;43(7):1441-1448. doi: 10.1016/j.burns.2017.04.017. Epub 2017 Aug 10.

PMID:
28803724
50.

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

Terrenato I, Sperati F, Musicco F, Pozzi AF, di Turi A, Caterino M, de Lutio di Castelguidone E, Setola SV, Bellomi M, Neumaier CE, Conti L, Cigliana G, Merola R, Antenucci A, Orlandi G, Giordano A, Barba M, Canitano S.

J Cell Physiol. 2018 Mar;233(3):2572-2580. doi: 10.1002/jcp.26132. Epub 2017 Sep 12.

PMID:
28777459

Supplemental Content

Support Center